PMID- 23701276
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20211021
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Print)
IS  - 1389-4501 (Linking)
VI  - 14
IP  - 8
DP  - 2013 Jul
TI  - Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular 
      neovascular diseases.
PG  - 919-35
AB  - Constant oxygen supply is essential for proper tissue development, homeostasis 
      and function of all eukaryotic organisms. Cellular response to reduced oxygen 
      levels is mediated by the transcriptional regulator hypoxia-inducible factor-1 
      (HIF-1). It is a heterodimeric complex protein consisting of an oxygen dependent 
      subunit (HIF-1alpha) and a constitutively expressed nuclear subunit (HIF-1beta). In 
      normoxic conditions, de novo synthesized cytoplasmic HIF-1alpha is degraded by 26S 
      proteasome. Under hypoxic conditions, HIF-1alpha is stabilized, binds with HIF-1beta and 
      activates transcription of various target genes. These genes play a key role in 
      regulating angiogenesis, cell survival, proliferation, chemotherapy, radiation 
      resistance, invasion, metastasis, genetic instability, immortalization, immune 
      evasion, metabolism and stem cell maintenance. This review highlights the 
      importance of hypoxia signaling in development and progression of various vision 
      threatening pathologies such as diabetic retinopathy, retinopathy of prematurity, 
      age-related macular degeneration and glaucoma. Further, various inhibitors of 
      HIF-1 pathway that may have a viable potential in the treatment of 
      oxygen-dependent ocular diseases are also discussed.
FAU - Vadlapatla, Ramya Krishna
AU  - Vadlapatla RK
AD  - Division of Pharmaceutical Sciences, School of Pharmacy, University of 
      Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA.
FAU - Vadlapudi, Aswani Dutt
AU  - Vadlapudi AD
FAU - Mitra, Ashim K
AU  - Mitra AK
LA  - eng
GR  - R01 EY009171/EY/NEI NIH HHS/United States
GR  - R01 EY010659/EY/NEI NIH HHS/United States
GR  - R01EY010659/EY/NEI NIH HHS/United States
GR  - R01EY09171/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Cell Hypoxia
MH  - Child
MH  - Eye Diseases/*drug therapy/metabolism
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/antagonists & 
      inhibitors/chemistry/genetics/*metabolism
MH  - *Molecular Targeted Therapy
MH  - Oxygen/*metabolism
MH  - Retinal Diseases/*drug therapy/metabolism
MH  - Signal Transduction
PMC - PMC4407697
MID - NIHMS680944
COIS- Conflict of Interest: The authors confirm that this article content has no 
      conflicts of interest.
EDAT- 2013/05/25 06:00
MHDA- 2014/01/22 06:00
PMCR- 2015/04/23
CRDT- 2013/05/25 06:00
PHST- 2013/03/23 00:00 [received]
PHST- 2013/05/20 00:00 [accepted]
PHST- 2013/05/25 06:00 [entrez]
PHST- 2013/05/25 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
PHST- 2015/04/23 00:00 [pmc-release]
AID - CDT-EPUB-20130521-1 [pii]
AID - 10.2174/13894501113149990015 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2013 Jul;14(8):919-35. doi: 10.2174/13894501113149990015.